Receiving at least one dose of a covid-19 vaccine before the first infection is strongly associated with a reduced risk of developing post-covid-19 condition, commonly known as long covid, finds a study published by The BMJ today.
A decade after its first FDA approval, Takeda expands label of HyQvia to include rare autoimmune disorder
The FDA on Monday extended the label for Takeda’s HyQvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) as a maintenance therapy to prevent
January 17, 2024